| Literature DB >> 29121861 |
Wassana Prisingkorn1, Panita Prathomya1, Ivan Jakovlić2, Han Liu1, Yu-Hua Zhao3, Wei-Min Wang4.
Abstract
BACKGROUND: Global trend of the introduction of high levels of relatively cheap carbohydrates to reduce the amount of costly protein in the aquatic animal feed production has affected the aquaculture of an economically important cyprinid fish, blunt snout bream (Megalobrama amblycephala). This dietary shift has resulted in increased prevalence of metabolic disorders, often causing economic losses. High dietary intake of carbohydrates, associated with obesity, is one of the major causes of non-alcoholic fatty liver disease (NAFLD) in humans.Entities:
Keywords: Aquaculture; Fish; Hepatosomatic index; NAFLD; Neurodegenerative diseases
Mesh:
Substances:
Year: 2017 PMID: 29121861 PMCID: PMC5680769 DOI: 10.1186/s12864-017-4246-9
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Formulation and proximate composition of the two diets
| Control | HCBD | |
|---|---|---|
| Ingredient | ||
| Soybean meal | 35.50 | 34.00 |
| Rapeseed meal | 19.00 | 19.00 |
| Wheat bran | 1.20 | 1.20 |
| Fishmeal | 8.00 | 8.00 |
| Wheat flour | 18.00 | 26.30 |
| Soybean oil | 3.80 | 5.20 |
| Lysine | 0.30 | 0.30 |
| Ca(H2PO4) | 2.00 | 2.00 |
| Premixa | 1.00 | 1.00 |
| Choline chloride | 1.00 | 1.00 |
| Carboxymethyl cellulose | 2.00 | 2.00 |
| Zeolite | 8.20 | 0.00 |
| Proximate composition (%) | ||
| Protein | 30.84 | 30.28 |
| Lipid | 7.99 | 8.26 |
| Carbohydrate | 26.63 | 34.13 |
| Ashb | 16.61 | 8.78 |
| Moisture | 13.42 | 12.61 |
aMultivitamin and mineral premix for the herbivorous fish (Wuhan Haid Group Co., Ltd): 0.5% multivitamins and 0.5% minerals. bBecause we used a high level of zeolite minerals (8.20%) in the control diet, the total ash is also much higher
Fig. 1Photomicrographs of representative hematoxylin- and eosin-stained (a-d) and Oil red O-stained (E and F) histological liver sections of blunt snout bream fed control diet (a, c and e) and high-carbohydrate diet (b, d and f). Arrows indicate examples of a: normal hepatocytes with regular, round nuclei; b: swollen hepatocytes with large diffused lipid vacuoles, c: absent nucleus and d: abnormal nucleus. CV and IF labels indicate examples of central liver vein with abnormal endothelial cells and inflammatory infiltrate respectively. In the Oil red O-staining section, to evaluate lipid content in livers (e and f), lipids are stained red. Magnification ×400 (a, b, e and f) and ×1000 (c and d)
Fig. 2Serum biochemistry parameters associated with liver damage. * above bar indicates significant difference (P < 0.05) and ** indicates highly significant difference (P < 0.01). Results were analyzed by t-test
Fig. 3Metabolites in plasma and liver extracts significantly different between the control and HCBD diet groups. a Plasma metabolomics and b Liver metabolomics. Results were analyzed by t-test. * above bars indicates significant difference (P < 0.05) and ** indicates highly significant difference (P < 0.01)
Fig. 4Transcriptome profiles of the HCBD and control groups. a GO annotation of all unigenes and DEG (differentially expressed) unigenes; b MA plot of differential gene expression levels in the two groups, where expression intensity is on the x-axis (log2 FPKM) and differences in the gene expression levels (fold change) are on the y-axis (log2 FC), each dot represents one gene, the log2 (FC) is plotted against the mean expression level for each gene, red dots represent genes whose abundance is significantly up-regulated, green dots - down-regulated, and black dots unchanged (or non-significantly changed) regulation; c COG annotation of and DEGs; d KEGG annotation of and DEGs
Fig. 5Expression of 13 DEGs from the transcriptome analysis associated with NAFLD, studied by qPCR. Data were normalized to 18 s rRNA and Rpl13a as reference genes and presented as a fold change between the control and HCBD groups (mean ± SE). HCBD is the high-carbohydrate diet group. Results were analyzed by t-test. (*) above bar indicates significant (P < 0.05) and (**) highly significant differences (P < 0.01)
Differentially expressed genes in liver transcriptome profiles of control and HCBD groups associated with non-alcoholic fatty liver disease pathway (a) and insulin signaling pathway (b) in KEGG database
| Gene Name | KEGG Number | Nr_annotation | FDR | log2FC | Regulation |
|---|---|---|---|---|---|
| SOCS3a,b | K04696 | Suppressor of cytokine signaling 3b ( | 0.009144 | −2.802 | Down |
| INSRa,b | K04527 | Insulin receptor a precursor ( | 0.272547 | 1.070 | Up |
| IRSa,b | K07187 | Insulin receptor substrate 2-B-like ( | 0.013461 | 1.903 | Up |
| PI3Ka,b | K02649 | Phosphatidylinositol 3-kinase regulatory subunit beta, partial ( | 0.048268 | −5.230 | Down |
| PDK1b | K06276 | 3-phosphoinositide-dependent protein kinase 1 isoform X1 ( | 0.050913 | 1.603 | Up |
| Akta,b | K04456 | RAC-gamma serine/threonine-protein kinase ( | 0.000433 | 6.580 | Up |
| GSK3a,b | K03083 | Glycogen synthase kinase-3 beta-like ( | 3.08E-13 | −8.657 | Down |
| K03083 | Glycogen synthase kinase-3 beta-like isoform X3 ( | 0.002352 | −6.405 | Down | |
| AMPKa,b | K07198 | MAP/microtubule affinity-regulating kinase 3 ( | 8.08E-13 | −8.608 | Down |
| K07198 | MAP/microtubule affinity-regulating kinase 3 ( | 0.038900 | −5.459 | Down | |
| K07198 | Serine/threonine-protein kinase MARK1-like ( | 0.012837 | −5.540 | Down | |
| ACCb | K11262 | Acetyl-CoA carboxylase 2 isoform X2 ( | 1 | 0.369 | Up |
| AP-1a | K04448 | Transcription factor AP-1 ( | 5.72E-05 | 6.614 | Up |
| PEPCKb | K01596 | Phosphoenolpyruvate carboxykinase ( | 0.002169 | 5.994 | Up |
| FBPb | K03841 | Fructose-1,6-bisphosphatase 1-like ( | 0.007951 | 6.039 | Up |
| K03841 | Fructose-1,6-bisphosphatase 1-like isoform X3 ( | 0.007492 | 6.142 | Up | |
| K03841 | Fructose-1,6-bisphosphatase 1-like ( | 1.95E-10 | −8.129 | Down | |
| K03841 | Fructose-1,6-bisphosphatase 1-like ( | 0.020039 | −5.485 | Down | |
| K03841 | Fructose-1,6-bisphosphatase 1-like ( | 0.040649 | −5.577 | Down |
aNon-alcoholic fatty liver disease pathway (ko04932), bInsulin signaling pathway (ko04910)
Fig. 6A hypothetical mechanism through which the observed changes in transcriptome, serum biochemistry, and serum and liver metabolomics caused by high-carbohydrate diet can lead to fatty liver disease